Jan Medical, a Mountain View, CA-based medical technology company, secured $7.5m in Series C funding.<
Brainlab, Inc., a global leader in medical technology, made the investment.
The company intends to use the funds to complete ongoing clinical trials and filing of product de novo with the FDA and CE Mark registration in the EU for BrainPulse™.
Led by Paul Lovoi, PhD, President and CEO, Jan Medical has developed BrainPulse, a novel, non-invasive, portable brain sensing system designed as a rapid aid to help diagnose abnormal neurological conditions such as concussion and stroke.
The device captures a physiological signal that utilizes the cardiac output to measure vasculature and brain tissue conditions. The data has the potential to impact non-invasive neurodiagnostics and provide a clinically relevant aid to diagnoses for a range of indications, including concussion and stroke.
Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.
In addition to the Series C funding, the company will provide resources to assist in ongoing clinical research, regulatory filing and commercialization activities, as well as expertise in research and development. Ken Bruener, Vice President of Marketing and Business Development, Brainlab, will become the Brainlab representative on the Jan Medical Board of Directors.